BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$78.17−1.37 (-1.72%)
Close on Nov 12, 2026Market cap $15.23BP/E –Yield –
BridgeBio Pharma r&d expenses
Research and development expenses are spending on new products and technology.
BridgeBio Pharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $536.01M, up 15.1% year over year. For fiscal 2025 it was $451.95M, down 10.8% from the year before. The highest annual figure on record is $506.46M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $451.95M | -10.8% |
| FY2024 | Dec 31, 2024 | $506.46M | +11.1% |
| FY2023 | Dec 31, 2023 | $455.71M | +14.1% |
| FY2022 | Dec 31, 2022 | $399.46M | -11.4% |
| FY2021 | Dec 31, 2021 | $451.02M | +33.8% |
| FY2020 | Dec 31, 2020 | $337.05M | +60.5% |
| FY2019 | Dec 31, 2019 | $209.95M | +49.9% |
| FY2018 | Dec 31, 2018 | $140.07M | +358.4% |
| FY2017 | Dec 31, 2017 | $30.56M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $143.51M | +27.1% |
| Q2 FY2026 | Jun 30, 2026 | $149.45M | +34.4% |
| Q1 FY2026 | Mar 31, 2026 | $126.64M | +13.6% |
| Q4 FY2025 | Dec 31, 2025 | $116.42M | -10.7% |
| Q3 FY2025 | Sep 30, 2025 | $112.87M | -6.3% |
| Q2 FY2025 | Jun 30, 2025 | $111.23M | -3.0% |
| Q1 FY2025 | Mar 31, 2025 | $111.43M | -21.0% |
| Q4 FY2024 | Dec 31, 2024 | $130.35M | +0.1% |
| Q3 FY2024 | Sep 30, 2024 | $120.44M | -3.7% |
| Q2 FY2024 | Jun 30, 2024 | $114.70M | +6.7% |
| Q1 FY2024 | Mar 31, 2024 | $140.97M | +51.8% |
| Q4 FY2023 | Dec 31, 2023 | $130.23M | +43.3% |
| Q3 FY2023 | Sep 30, 2023 | $125.14M | +35.3% |
| Q2 FY2023 | Jun 30, 2023 | $107.49M | -0.8% |
| Q1 FY2023 | Mar 31, 2023 | $92.86M | -13.7% |
| Q4 FY2022 | Dec 31, 2022 | $90.90M | -25.6% |
| Q3 FY2022 | Sep 30, 2022 | $92.51M | -11.3% |
| Q2 FY2022 | Jun 30, 2022 | $108.40M | +6.3% |
| Q1 FY2022 | Mar 31, 2022 | $107.65M | -12.2% |
| Q4 FY2021 | Dec 31, 2021 | $122.20M | +35.5% |
| Q3 FY2021 | Sep 30, 2021 | $104.31M | +13.3% |
| Q2 FY2021 | Jun 30, 2021 | $101.96M | +17.7% |
| Q1 FY2021 | Mar 31, 2021 | $122.56M | +79.6% |
| Q4 FY2020 | Dec 31, 2020 | $90.17M | +56.9% |
| Q3 FY2020 | Sep 30, 2020 | $92.05M | +66.5% |
| Q2 FY2020 | Jun 30, 2020 | $86.60M | +65.5% |
| Q1 FY2020 | Mar 31, 2020 | $68.23M | +52.1% |
| Q4 FY2019 | Dec 31, 2019 | $57.49M | +12.3% |
| Q3 FY2019 | Sep 30, 2019 | $55.28M | +77.5% |
| Q2 FY2019 | Jun 30, 2019 | $52.33M | – |
| Q1 FY2019 | Mar 31, 2019 | $44.85M | – |
| Q4 FY2018 | Dec 31, 2018 | $51.20M | – |
| Q3 FY2018 | Sep 30, 2018 | $31.15M | – |
See a number that looks wrong?